Irlanda - inglês - HPRA (Health Products Regulatory Authority)

leo pharma a/s - protamine sulphate - solution for injection/infusion - 1400 international unit(s)/millilitre - antidotes; protamine

Malta - inglês - Medicines Authority

leo pharma a/s industriparken 55, 2750-dk ballerup, denmark - protamine sulfate - solution for injection/infusion - protamine sulfate 10 mg/ml - all other therapeutic products

Estados Unidos - inglês - NLM (National Library of Medicine)

northstar rx llc - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection, usp is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection, usp is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who ha

Estados Unidos - inglês - NLM (National Library of Medicine)

cipla usa inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. lymphomas hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin has also been shown to be useful in the management of: malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to i

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms: = squamous cell carcinoma of the skin, head and neck, and oesophagus (primary indication). = squamous cell carcinoma of the larynx, penis and uterine cervix. = squamous cell carcinoma of the bronchus (response infrequent). = choriocarcinoma and embryonal cell carcinoma of the testis. = advanced hodgkin's disease and other lymphomas. = mycosis fungoides.,note. use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

macleods pharmaceuticals sa (pty) ltd - injection - see ingredients - each vial contains hydrocortisone sodium succinate equivalent to hydrocortisone 100,0 mg

Quênia - inglês - Pharmacy and Poisons Board

bleomycin sulfate usp - injection - bleomycin sulfate usp – 15units/vial - bleomycin

Canadá - inglês - Health Canada

sandoz canada incorporated - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents

Canadá - inglês - Health Canada

fresenius kabi canada ltd - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents